BioSpace News Archive

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), today reported financial results for the second quarter ended June 30, 2022 and corporate highlights.

Gravity Branding, the agency behind naming blockbuster drugs including Novartis’ Kisqali® (ribociclib), Genentech’s Herceptin® (trastuzumab) and Janssen’s Concerta® (methylphenidate HCl), recently announced its success naming Vijoice® (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the second quarter of 2022.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results and provided a business update for the second quarter ended June 30, 2022.

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter ended June 30, 2022.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2022 financial results.

Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the second quarter ended June 30, 2022.

Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Ligand Pharmaceuticals Incorporated today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates.

Quanterix Corporation, a company expanding the limits of exploration with ultrasensitive biomarker detection, announced operating results for the three months ended June 30, 2022.